Use of cannabinoids in palliative medicine;Bruk av cannabinoider i palliativ medisin

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 7, 2008, Pages 822-825

  Ernst, Gernot ^a   Kongsgaard, Ulf E ^b,c  

^a Blefjell Sykehus Kongsberg   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CANNABINOID; CANNABINOID RECEPTOR; TETRAHYDROCANNABINOL;

APPETITE; DRUG EFFECT; HUMAN; METHODOLOGY; NAUSEA; NEURALGIA; PAIN; PALLIATIVE THERAPY; PRURITUS; REVIEW;

ANALGESICS, NON-NARCOTIC; ANTIEMETICS; APPETITE; CANNABINOIDS; HUMANS; NAUSEA; NEURALGIA; PAIN; PALLIATIVE CARE; PRURITUS; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL;

EID: 42149185662     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Baines MJ. ABC of palliative care: nausea, vomiting, and intestinal obstruction. BMJ 1997; 315: 1148-50.
2. Higginson IJ, Hearn J, Addington-Hall J. Epidemiology of cancer pain. I: Sykes N, Fallon MT, Patt RB, red. Clinical pain management. Cancer Pain. London: Arnold, 2003: 22-32.
3. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006; 28: 153-7.
4. Mechoulam R, Gaoni Y. Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 1965; 21: 1223-9.
5. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
6. Pertwee RG. Cannabinoid receptor signalling. Handb Exp Pharmacol 2005; 168: 1-51.
7. Khiabiani HZ, Mørland J. Cannabis og cannabinoider som legemidler. Tidsskr Nor Lægeforen 2007; 127: 579-82.
8. Noyes R jr, Brunk SF, Baram DA et al. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15: 139-43.
9. Noyes R jr, Brunk SF, Avery DAH et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 15: 84-9.
10. Raft D, Gregg J, Ghia J et al. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther 1977; 21: 26-33.
11. Buggy DJ, Toogood L, Maric S et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106: 169-72.
12. Zayicek J, Fox P, Sanders H et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study: multicentre randomised placebo-controlled trial). Lancet 2003; 362: 1517-26.
13. Karst M, Salim K, Burstein S et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757-62.
14. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112: 299-306.
15. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis. Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253.
16. Wade DT, Robson P, House H et al. A preliminary study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-9.
17. Wade DT, Makela P, Robson P et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-41.
18. Wade DT, Makela PM, House H et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-45.
19. Ernst G, Denke C, Reif M et al. Standardized cannabis extract in the treatment of postzosteric neuralgia - a randomized, double-blind, placebo-controlled cross-over study. Sydney: IASP world congress on pain, 2005: 1020(P626).
20. Rog DJ, Nurmikko TJ, Friede T et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-9.
21. Johnson JR, Davison A, The Investigator group GWCA0101. Cannabis-based medicines in the treatment of cancer pain - preliminary results. Sydney: IASP World Congress on Pain, 2005: 1081(P323).
22. Blake DR, Robson P, Ho M et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 1-50.
23. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006; 53: 769-75.
24. Abrams DI, Jaz CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68: 515-21.
25. Campbell FA, Tramer MR, Carroll D et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-6.
26. Holdcroft A, Maye M, Dore C et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104: 1040-6.
27. Naef M, Curatolo M, Petersen-Felix S et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105: 79-88.
28. Cichewicz DL, Welch SP, Smith FL. Enhancement of transdermal fentanyl and buprenorphine antinociseption by transdermal delta9-tetrahydrocannabinol. Eur J Pharmacol 2005; 525: 74-82.
29. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interactions between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006; 530: 54-8.
30. Jordhøy MS, Aass N, Svensen R et al. Kvalme, oppkast og obstipasjon i palliasjonsbehandling. Tidsskr Nor Lægeforen 2006; 126: 620-23.
31. Ungerleider JT, Andrysiak T, Fairbanks L et al. Cannabis and cancer chemotherapy: a comparison of oral Delta-9-Tetrahydrocannabinol and prochlorperazine. Cancer 1982; 50: 636-45.
32. Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8: 336-40.
33. Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 1986; 3: 39-42.
34. Pomeroy M, Fenelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986; 17: 285-8.
35. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986; 61: 502-5.
36. Tramer M, Carroll D, Campbell FA et al. Cannabinoids for the control of chemotherapy induced nausea and vomiting: quantitative systemic review. BMJ 2001; 323: 16-21.
37. Mattes RD, Engelman K, Shaw LM et al. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994; 49: 187-95.
38. Beal JE, Olson R, Laubenstein L et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89-97.
39. Walsh D, Kirkova J, Davis MP. The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series (letter). J Pain Symptom Manage 2005; 30: 493-5.
40. Jatai A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. J Clin Oncol 2002; 20: 567-73.
41. Strasser F, Luftner D, Possinger K et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo controlled clinical trial from the cannabisin cachexia-study-group. J Clin Oncol 2006; 24: 3394-400.
42. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-49.
43. Schmidt S. Cannabis. I: Hänsel R, Keller K, Rimpler H et al, red. Hagers Handbuch der pharmaceutischen Praxis. Berlin: Springer, 1992.
44. Messinis L, Kyprianidou A, Malefaki S et al. Neuropsychological deficits in long-term frequent cannabis users. Neurology 2006; 66: 737-9.
45. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007; 4: 1744-69.
46. Paus R, Schmelz M, Biro T et al. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006; 116: 1174-86.
47. Martin WJ, Loo CM, Basbaum AI. Spinal cannabinoids are antiallodynic in rats with persistent inflammation. Pain 1999; 82: 199-205.
48. Twycross R. Cancer pain syndromes I: Sykes N, Fallon MT, Patt RB, red. Clinical pain management. Cancer Pain. London: Arnold, 2003: 3-19.
49. Jackson K, Ashby M, Martin P et al. «Burst» ketamine for refractory cancer pain: an open label audit of 39 patients. J Pain Symptom Manage 2001; 22: 834-42.
50. Kwiatkowska M, Parker LA, Burton P et al. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacol (Berl) 2004; 174: 254-9.
51. Parker LA, Kwiatkowska M, Mechoulam R. Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiol Behav 2006; 87: 66-71.
52. Nordøy T, Thoresen L, Kvikstad A et al. Ernæring og væskebehandling til pasienter med ikke-kurabel kreftsykdom. Tidsskr Nor Lægeforen 2006; 126: 624-7.
53. Bruera E, Castro M. Cannabinoids in supportive care: are they necessary? Support Care Cancer 2003, 11: 133-4.
54. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-70.
55. Hall W, MacDonald C, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 2005; 6: 35-42.